Recent changes in company positions were made by various hedge funds and institutional investors. KBC Group NV purchased a new stake in Natera worth $141,000 in Q4. Natixis Investment Managers increased their shares by 28.1%, now owning 2,902 shares valued at $182,000. Sirios Capital Management grew their stake by 30.2%, owning 15,089 shares worth $945,000 after acquiring 3,500 shares. Avidity Partners raised their holdings by 23.5%, now owning 1,110,000 shares valued at $69.53 million. Lastly, Cubist Systematic Strategies boosted their stake by 180.7%, owning 224,026 shares worth $14.03 million. Institutional investors hold 99.90% of the stock.
Analysts Set New Price Targets
Several analysts have updated their price targets for Natera (NTRA). Robert W. Baird raised their target from $117 to $120 with an outperform rating. BTIG Research increased theirs from $125 to $135, maintaining a buy rating. Stephens set a price target of $125, while TD Cowen raised theirs from $137 to $145. Canaccord Genuity changed theirs from $130 to $145, also giving a buy rating. One analyst rated it as a sell, while 15 assigned a buy rating, resulting in an average rating of Moderate Buy with a consensus target price of $120.07.
Natera Stock Performance
Natera stock (NTRA) opened at $129.84. It has a 50-day moving average of $118.35 and a 200-day average of $108.08. The stock has ranged from a low of $36.90 to a high of $132.01 over the past year and has a market cap of $15.94 billion. Recently, Natera reported quarterly earnings, with an EPS of ($0.30), exceeding expectations of ($0.69), and revenue of $413.35 million against an estimate of $343 million. Revenue increased 58.1% year-over-year.
Insider Activity at Natera
CEO Steven Leonard Chapman sold 5,496 shares on July 15 for $613,683, reducing his ownership to 207,855 shares valued at about $23.21 million. Insider Solomon Moshkevich sold 549 shares on July 22 for $57,732, maintaining ownership of 113,637 shares worth $11.95 million. Insiders sold 51,738 shares totaling $6.04 million in the last 90 days, with insiders owning 7.60% of the company.
Natera Company Profile
Natera, Inc. specializes in molecular testing services. Their products include Panorama (prenatal tests), Horizon (carrier screening), Vistara (single-gene tests), Spectrum (IVF tests), and hereditary cancer screenings. They provide several diagnostics services focused on genetic conditions.
Further Reading
- Five stocks we like better than Natera
- How to Invest in Small Cap Stocks
- 3 Key Stocks to Ride Chinas Stimulus-Driven Growth
- Top Biotech Stocks: Exploring Innovation Opportunities
- 3 Dividend Growth Stocks Set to Supercharge Your Portfolio
- What Is WallStreetBets and What Stocks Are They Targeting?
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com for the latest institutional filings and insider trades for Natera, Inc.
Receive Daily News & Ratings for Natera – Enter your email below for a summary of the latest news and analyst ratings for Natera and related companies with MarketBeat.com’s FREE daily email newsletter.
`
